중국의 생물제제 수탁제조 시장 : 업계 동향과 세계 예측 - 제품 유형별, 사용 발현 시스템별, 사업 규모별, 기업 규모별, 생물제제 유형별
China Biologics Contract Manufacturing Market: Industry Trends and Global Forecasts - Distribution by Type of Product, Expression System Used, Scale of Operation, Company Size and Type of Biologic
상품코드:1762537
리서치사:Roots Analysis
발행일:2025년 07월
페이지 정보:영문 281 Pages
라이선스 & 가격 (부가세 별도)
한글목차
중국의 생물제제 수탁제조 시장 : 개요
중국의 생물제제 수탁제조 시장 규모는 올해 8억 달러에 달했습니다. 이 시장은 예측 기간 중 13%의 CAGR로 확대할 것으로 예측됩니다.
시장 세분화 및 기회 분석은 다음과 같은 매개 변수로 세분화됩니다.
제품 유형
API
FDF
사용 발현 시스템
포유류 시스템
미생물 시스템
기타
사업 규모
전임상/임상 규모 운영
상업 운영
기업 규모
소규모 기업
중견기업
대기업/초대형 기업
생물제제 유형
항체
백신
기타
중국 생물제제 수탁제조 시장 : 성장과 동향
생물제제는 제약 산업에서 가장 빠르게 성장하는 분야 중 하나입니다. 이는 효과적이고 개별화된 약리학적 개입의 필요성으로 인해 이 분야의 기술 혁신이 빠르게 진행되고 있기 때문입니다. 특히 COVID-19 팬데믹의 진원지였던 중국은 세계 2위의 의약품 시장으로 전 세계 원료의약품 생산량의 약 20%를 차지하고 있습니다. 또한 현재까지 25개 이상의 생물제제와 바이오시밀러 제품이 승인되었고, 다양한 생물제제와 바이오시밀러의 연구를 위해 1,000개에 가까운 임상시험이 진행되고 있으며, 중국의 생물제제 수탁제조 시장은 건강한 속도로 성장하고 있습니다. 이와는 별도로, 낮은 제조 비용, 풍부한 상환 정책, 저렴하고 숙련된 노동력의 가용성, 지원적인 규제 상황과 같은 몇 가지 매력은 중국이 생물제제 수탁제조 시장에 종사하는 다양한 이해관계자들에게 매력적인 선택이 될 수 있도록 촉진하고 있습니다.
이 분야에 종사하는 대부분의 위탁 서비스 프로바이더는 틈새 및 신흥 분야에 대한 깊은 경험을 가지고 있다는 점은 주목할 만합니다. 또한 선천적인 전문 지식과 필요한 역량, 인프라의 가용성을 통해 이러한 서비스 제공 업체는 고객의 요구 사항을 효과적으로 충족시킬 수 있으며, 동시에 비용이 많이 드는 간과를 없애고 제품 결함의 가능성을 줄일 수 있습니다.
중국 생물제제 수탁제조 시장 : 주요 인사이트
이 보고서는 중국의 바이오의약품 수탁제조 시장 현황을 조사하고, 잠재적인 성장 기회를 파악하고자 합니다. 주요 조사 결과는 다음과 같습니다.
중국의 35개 이상의 CMO/CDMO는 다양한 바이오 치료 제품의 개발 및 제조와 관련된 다양한 서비스를 제공한다고 주장하고 있습니다.
여러 기업이 원스톱 솔루션을 제공하며 다양한 규모로 사업을 전개하고 있습니다.
현재, 신규 생물제제 생산 능력을 보유하고 있다고 주장하는 기업은 소수에 불과합니다.
아시아태평양에서 생물제제의 비즈니스 기회를 확대하기 위해 중국은 CMO에게 선호되는 선택지가 되고 있습니다.
CMO는 고객과 스폰서의 진화하는 요구에 부응하기 위해 중국내 여러 지역에 시설을 설립하고 있습니다.
지난 5년 동안 80건 이상의 거래가 체결되어 이 분야의 제휴 활동이 급증하고 있습니다. 이러한 제휴의 대부분은 항체 기반 제품의 개발 및 제조를 위해 체결된 것입니다.
이 분야에서 체결된 파트너십의 수는 지난 수년간 CAGR 21%로 증가했습니다.
보고된 거래의 60% 이상이 임상 단계의 분자와 관련하여 체결되었습니다.
대형 제약사들도 생물제제를 중심으로 신규 시설 설립, 기존 연구개발센터 확장, 제조시설 보강 등 이 지역에 많은 투자를 하고 있습니다.
화이자는 3억 5,000만 달러를 투자하여 중국 항저우에 고품질 바이오시밀러를 생산할 수 있는 최첨단 세계 바이오테크놀러지 센터를 신설하여 국내외 수요에 대응할 예정입니다.
머크는 GenScript와 제휴하여 중국 및 세계 시장에서 세포 및 유전자 치료제의 개발 및 상용화를 촉진하기 위해 플라스미드 및 바이러스 벡터 생산 플랫폼을 구축했습니다.
이 지역의 CMO 산업은 2030년까지 연평균 13% 성장할 것으로 예측됩니다.
중국 생물제제 수탁제조 시장의 참여 기업 예
ChemPartner Biologics
JHL Biotech
JOINN Biologics
MabPlex
Mycenax Biotech
WuXi AppTec
목차
제1장 서문
제2장 개요
제3장 서론
챕터 개요
생물제제의 개요
생물제제의 제조
계약 제조의 개요
생물제제 업계에서 아웃소싱의 필요성
생물제제 업계에서 일반적으로 아웃소싱되는 업무
CMO 파트너 선정 기본 가이드라인
제조 서비스 아웃소싱의 이점
생물제제 계약 제조에 수반하는 리스크와 과제
향후 전망
제4장 사례 연구 : 저분자와 대분자의 비교
챕터 개요
저분자 및 고분자 의약품/치료법
제5장 경쟁 구도
챕터 개요
중국의 생물제제 수탁제조 업자 : 시장 구도
제6장 기업 개요
챕터 개요
ChemPartner Biologics
JHL Biotech
JOINN Biologics
MabPlex
Mycenax Biotech
WuXi AppTec
제7장 파트너십
챕터 개요
파트너십 모델
중국의 생물제제 수탁제조 업자 : 최근 제휴
제8장 최근 확장
챕터 개요
중국의 생물제제 수탁제조 업자 : 최근 확대
제9장 임상시험 분석
챕터 개요
범위와 조사 방법
임상시험 분석 : 생물제제
제10장 지역 능력 분석
챕터 개요
전제와 주요 파라미터
중국의 생물제제 수탁제조 업자 전체 상황
지역적 능력 분석 : 중국 북부 생물제제 수탁제조 업자
지역적 능력 분석 : 중국 동부 생물제제 수탁제조 업자
지역적 능력 분석 : 중국 중부 생물제제 수탁제조 업자
지역적 능력 분석 : 중국 남부 생물제제 수탁제조 업자
제11장 용량 분석
챕터 개요
전제와 조사 방법
중국의 생물제제 수탁제조 업자 : 설치용량
결론
제12장 중국에서 대형 제약회사 생물제제 제조구상
챕터 개요
중국 대형 제약회사 생물제제 연구개발·제조 구상 리스트
대형 제약회사의 경쟁 벤치마킹
제13장 제조인가 구입인가 의사 의사결정 프레임워크
챕터 개요
전제와 주요 파라미터
중국의 생물제제 수탁제조 업자 : 제조인가 구입인가 의사결정
결론
제14장 시장 규모의 평가와 기회 분석
챕터 개요
주요 전제와 예측 조사 방법
중국에서 생물제제 수탁제조 시장(-2035년)
중국의 생물제제 수탁제조 시장(-2035년) : 사용 발현 시스템별
중국의 생물제제 수탁제조 시장(-2035년) : 사업 규모별
중국의 생물제제 수탁제조 시장(-2035년) : 기업 규모별
중국의 생물제제 수탁제조 시장(-2035년) : 생물제제 유형별
제15장 COVID-19별 중국 생물제제 CMO 시장에 대한 영향
챕터 개요
주요 참여 기업의 현재의 의견과 회복구상
WuXi AppTec
Boehringer Ingelheim
GE Healthcare
Lonza
AmbioPharm
중국 생물제제 수탁제조 시장에 대한 영향
제16장 SWOT 분석
제17장 중국 생물제제 CMO 시장의 미래
챕터 개요
아웃소싱 활동은 향후 증가할 것으로 예상된다.
단발 계약으로부터 전략적 파트너십으로의 이동
혁신적 기술의 도입
바이오프로세스에서 설계 품질 원칙의 보급
니치 치료 영역에 대한 중점화
바이오시밀러 시장이 계약 서비스 매출에 기여
원스톱 숍 전문성을 확립하기 위한 능력과 시설의 확장
자금 유입과 아웃소싱 예산의 증가
스폰서와 서비스 프로바이더가 직면하는 과제
결론
제18장 인터뷰 기록
제19장 부록 1 : 표형식 데이터
제20장 부록 2 : 기업·단체 리스트
KSA
영문 목차
영문목차
CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: OVERVIEW
As per Roots Analysis, the global China biologics contract manufacturing market valued at USD 0.8 billion in the current year is anticipated to grow at a CAGR of 13% during the forecast period.
The market sizing and opportunity analysis has been segmented across the following parameters:
Type of Product
APIs
FDFs
Expression System Used
Mammalian Systems
Microbial Systems
Other Expression Systems
Scale of Operation
Preclinical / Clinical Scale Operations
Commercial Operations
Company Size
Small Companies
Mid-sized Companies
Large / Very Large Companies
Type of Biologic
Antibodies
Vaccines
Other Biologics
CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS
Biologics represent one of the fastest growing segments of the pharmaceutical industry. This can
be attributed to the rapid pace of innovation in this field, driven by the need for effective and personalized pharmacological interventions. Notably, China which was the epicenter of the COVID-19 pandemic, is the world's second largest pharmaceutical market and accounts for nearly 20% of the global output of APIs. Further, with over 25 biologics and biosimilar products approved till date and close to 1,000 clinical trials being conducted to investigate a variety of biologics and biosimilars, the biologics contract manufacturing market in China is growing at a healthy pace. Apart from this, several benefits, such as lower manufacturing costs, enhanced reimbursement policies, availability of cheap and skilled labor and a supportive regulatory landscape, has facilitated China in becoming an attractive choice for various stakeholders engaged in the biologics contract manufacturing market.
It is worth noting that most of the contract service providers engaged in this domain have profound experience in niche and emerging areas. In addition, the innate expertise and availability of required capabilities, as well as infrastructure, enables such service providers to effectively fulfil the requirements of their clients, while eliminating costly oversights and reducing chances of product failure.
CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY INSIGHTS
The report delves into the current state of the China biologics contract manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:
Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development and manufacturing of a wide range of biotherapeutic products.
Several players provide one-stop solutions and are capable of operating at various scales; the landscape includes a mix of both established players and new entrants.
At present, only a handful of firms claim to have capabilities for the manufacturing of novel biologics.
In order to tap the increasing opportunity for biologics in Asia-Pacific, China has emerged a preferred choice for CMOs.
To cater to the evolving needs of clients / sponsors, CMOs have established facilities across different regions of China; Eastern China, with the maximum number of sites, has emerged as a manufacturing hub.
With over 80 deals inked in past five years, there has been a surge in the partnership activity within this domain; majority of these collaborations were signed for the development and manufacturing of antibody-based products.
The number of partnerships signed within this domain has increased at a CAGR of 21% in the past few years.
More than 60% of the reported deals were inked in relation to clinical stage molecules.
Big pharma players have also made significant investments in this region, including establishing new facilities, expanding existing R&D centers and growing manufacturing facilities, focused on biotherapeutics.
Pfizer invested USD 350 million to establish a new state-of-art global biotechnology center in Hangzhou, China for the production of high quality biosimilars to meet both local and international demand.
Merck partnered with GenScript to establish a plasmid and viral vector manufacturing platform in order to expediate development and commercialization of cell and gene therapies in Chinese and global market.
We expect global biopharmaceutical developers to continue to outsource their manufacturing operations to China in the long term; the CMO industry in the region is likely to grow at an annualized rate of ~13%, till 2030.
Example Players in the China Biologics Contract Manufacturing Market
ChemPartner Biologics
JHL Biotech
JOINN Biologics
MabPlex
Mycenax Biotech
WuXi AppTec
CHINA BIOLOGICS CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE
Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the China biologics contract manufacturing market, focusing on key market segments, including [A] type of product, [B] expression system used, [C] scale of operation, [D] company size and [E] type of biologic.
Market Landscape: A comprehensive evaluation of companies offering contract manufacturing services for biopharmaceuticals in China, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] scale of operation, [D] location of headquarters, [E] number of manufacturing facilities, [F] location of facilities, [G] type of business segment, [H] type of manufacturing service(s) offered, [I] type of biologic(s) manufactured, [J] type of expression system(s) used, [K] type of bioreactor(s) used, [L] mode of operation, [M] type of packaging and [N] affiliations to regulatory accreditations and certifications.
Partnerships and Collaborations: An insightful analysis of the deals inked by stakeholders in the biopharmaceutical manufacturing market in China, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] scale of operation, [D] type of biologic, [E] focus area of the deal, [F] target indication, [G] most active players (in terms of number of partnerships signed) and [H] geography.
Recent Expansions: A comprehensive evaluation of expansion initiatives undertaken by contract manufacturers in China, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] scale of operation of manufacturing facility, [D] type of biologic and [E] location of manufacturing facility.
Clinical Trial Analysis: An insightful analysis of clinical trials related to biopharmaceuticals conducted in China, based on several parameters, such as [A] trial registration year, [B] trial phase, [C] trial recruitment status, [D] type of sponsor / collaborator, [E] geography and [F] number of patients enrolled.
Capacity Analysis: A detailed analysis of installed capacity for manufacturing biopharmaceuticals in China, based on several parameters, such as [A] company size, [B] scale of operation, [C] key geographical regions and [D] expression system used.
Big Pharma Initiatives: A comprehensive analysis of the recent initiatives undertaken by big pharma players in China for the manufacturing of biopharmaceuticals, based on various relevant parameters, such as [A] number of initiatives, [B] year of initiative and [C] benchmark analysis of big pharma players.
Make Versus Buy Decision Making Framework: A detailed qualitative analysis, focusing on the various factors that need to be considered by drug / therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Company Profiles: In-depth profiles of the companies that have a diverse range of capabilities for the development, manufacturing and packaging of biopharmaceutical products, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, [D] details related to manufacturing capabilities and facilities and [E] recent developments and an informed future outlook.
Case Study: A detailed comparison of the important characteristics of large and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of China biologics contract manufacturing market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.
KEY QUESTIONS ANSWERED IN THIS REPORT
How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?
REASONS TO BUY THIS REPORT
The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
ADDITIONAL BENEFITS
Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older
TABLE OF CONTENTS
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.2.1. Research Assumptions
1.2.2. Project Methodology
1.2.3. Forecast Methodology
1.2.4. Robust Quality Control
1.2.5. Key Considerations
1.2.5.1. Demographics
1.2.5.2. Economic Factors
1.2.5.3. Government Regulations
1.2.5.4. Supply Chain
1.2.5.5. COVID Impact / Related Factors
1.2.5.6. Market Access
1.2.5.7. Healthcare Policies
1.2.5.8. Industry Consolidation
1.3 Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Manufacturing Biopharmaceuticals
3.3.1. Types of Expression Systems Used
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Yeast Expression Systems
3.3.1.3. Insect Expression Systems
3.3.1.4. Plant Expression Systems
3.3.1.5. Mammalian Expression Systems
3.3.1.6. Fungal Expression Systems
3.3.2. Processing Steps
3.3.2.1. Upstream Processing
3.3.2.2. Downstream Processing
3.4. Overview of Contract Manufacturing
3.4.1. Contract Manufacturing Scenario in China
3.5. Need for Outsourcing in the Biopharmaceutical Industry
3.5.1. Biopharmaceutical Outsourcing in China: Regulatory Scenario
3.6. Commonly Outsourced Operations in the Biopharmaceutical Industry
3.7. Basic Guidelines for Selecting a CMO Partner
3.8. Advantages of Outsourcing Manufacturing Services
3.8.1. Benefits of Engaging Chinese Contract Service Providers
3.9. Risks and Challenges Associated with Biopharmaceutical Contract Manufacturing
3.9.1. Challenges Associated with Engaging Chinese Contract Service Providers
3.10. Future Perspective
4. CASE STUDY: COMPARISON OF SMALL MOLECULES AND LARGE MOLECULES
4.1. Chapter Overview
4.2. Small Molecule and Large Molecule Drugs / Therapies
4.2.1. Comparison of Key Characteristics
4.2.2. Comparison of Manufacturing Processes
4.2.3. Comparison of Key Manufacturing-Related Challenges
5. COMPETITIVE LANDSCAPE
5.1. Chapter Overview
5.2. Chinese Biopharmaceutical Contract Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Location of Headquarters
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Type of Product
5.2.7. Analysis by Types of Services Offered
5.2.8. Analysis by Type of Biologic
5.2.9. Analysis by Expression System Used
5.2.10. Analysis by Type of Bioreactor Used
5.2.11. Analysis by Mode of Operation of Bioreactor
5.2.12. Analysis by Packaging Form Used
5.2.13. Analysis by Regulatory Accreditations / Certifications
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. ChemPartner Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.2.1. Cell Line Development
6.2.2.2. Process Development
6.2.2.3. Formulation Development
6.2.2.4. Aseptic Filling and Freeze Drying
6.2.2.5. Drug Developability and Manuafcturing Study
6.2.2.6. Container Extractables and Leachables Study
6.2.2.7. Analytical Development and Testing
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Recent Developments and Future Outlook
6.3. JHL Biotech
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.2.1. Cell Line and Process Development
6.3.2.2. Analytical and Formulation Development
6.3.2.3. cGMP Manufacturing
6.3.2.4. Quality Systems
6.3.2.5. Regulatory Support
6.3.2.6. Project Management Services
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Recent Developments and Future Outlook
6.4. JOINN Biologics
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.2.1. Development Services
6.4.2.2. Manufacturing Services
6.4.2.3. Fill / Finish Services
6.4.2.4. Quality Assurance and Quality Control
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Recent Developments and Future Outlook
6.5 MabPlex
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.2.1. Development Services
6.5.2.2. GMP Manufacturing Services
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Recent Developments and Future Outlook
6.6. Mycenax Biotech
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.2.1. Cell Development Services
6.6.2.2. Process Development Services
6.6.2.3. Analytical and Quality Control
6.6.2.4. GMP Manuafacturing Services
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Recent Developments and Future Outlook
6.7. WuXi AppTec
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Service Portfolio
6.7.3.1. Discovery Sciences
6.7.3.2. Development Services
6.7.3.3. Testing Services
6.7.3.4. Clinical Manufacturing Services
6.7.3.5. Commercial Manufacturing Services
6.7.3.6. Fill / Finish Operations
6.7.4. Manufacturing Facilities and Capabilities
6.7.5. Recent Developments and Future Outlook
7. PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Chinese Biopharmaceutical Contract Manufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Therapeutic Area
7.3.7. Most Active Players: Analysis by Number of Partnerships
7.3.8. Geographical Analysis
7.3.8.1. Geographical Distribution by Number of Partnerships
7.3.8.2. Intercontinental and Intracontinental Agreements
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Chinese Biopharmaceutical Contract Manufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.2.5. Analysis by Location of Expansion Project
8.2.6. Analysis by Capacity of Expanded Facility
8.2.7. Most Active Players: Analysis by Number of Expansions
8.2.8. Analysis by Region
9. CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Clinical Trial Analysis: Biologic Drugs
9.3.1. Analysis by Trial Registration Year
9.3.2. Analysis by Trial Phase
9.3.3. Analysis by Trial Status
9.3.4. Geographical Analysis by Number of Clinical Trials
9.3.5. Geographical Analysis by Enrolled Patient Population
9.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
9.3.7. Analysis of Enrolled Patient Population by Trial Phase
9.3.8. Analysi by Type of Sponsor / Collaborator
9.3.9. Most Active Players: Analysis by Number of Registered Trials
9.3.10. Analysis by Clinical Trial Center
10. REGIONAL CAPABILITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Overall Landscape of Chinese Biopharmaceuticals Contract Manufacturers
10.4. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Northern China
10.5. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Eastern China
10.6. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Central China
10.7. Regional Capability Analysis: Biopharmaceuticals Contract Manufacturers in Southern China
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Chinese Biopharmaceutical Contract Manufactures: Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Expression System Used
11.3.4. Analysis by Location of Manufacturing Facility
11.3.5. Analysis by Company Size and Location of Manufacturing Facility
11.3.6. Analysis by Scale of Operation and Location of Manufacturing Facility
11.4. Concluding Remarks
12. BIG PHARMA BIOPHARMACEUTICAL MANUFACTURING INITIATIVES IN CHINA
12.1. Chapter Overview
12.2. List of Biopharmaceutical R&D and Manufacturing Initiatives of Big Pharma Players in China
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Company and Year of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Type of Biologic
12.3. Competitive Benchmarking of Big Pharmaceutical Players
12.3.1. Harvey Ball Analysis: Big Pharma Investment Summary
12.3.2. Geographical Analysis by Investment Made
13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
13.1. Chapter Overview
13.2. Assumptions and Key Parameters
13.3. Chinese Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
13.3.1. Scenario 1
13.3.2. Scenario 2
13.3.3. Scenario 3
13.3.4. Scenario 4
13.4. Conclusion
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035
14.3.1. Biopharmaceutical Contract Manufacturing Market in China for APIs, Till 2035
14.3.2. Biopharmaceutical Contract Manufacturing Market in China for FDFs, Till 2035
14.4. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Expression System Used
14.4.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Mammalian Systems
14.4.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Microbial Systems
14.4.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Other Expression Systems
14.5. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Scale of Operation
14.5.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Preclinical / Clinical Scale Operations
14.5.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Commercial Operations
14.6. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Company Size
14.6.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Small Companies
14.6.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Mid-sized Companies
14.6.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Large and Very Large Companies
14.7. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Distribution by Type of Biologic
14.7.1. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Antibodies
14.7.2. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Vaccines
14.7.3. Biopharmaceutical Contract Manufacturing Market in China, Till 2035: Share of Other Biologics
15 COVID-19 Impact on China Biopharmaceutical CMO Market
15.1. Chapter Overview
15.2. Current Opinions and Recuperative Initiatives of Key Players
15.2.1. WuXi AppTec
15.2.2. Boehringer Ingelheim
15.2.3. GE Healthcare
15.2.4. Lonza
15.2.5. AmbioPharm
15.2.6. Impact on China Biopharmaceutical Contract Manufacturing Market
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
16.7. Concluding Remarks
17. FUTURE OF THE CHINA BIOPHARMACEUTICAL CMO MARKET
17.1. Chapter Overview
17.2. Outsourcing Activities Anticipated to Increase in Future
17.3. Shift from One-time Contracts to Strategic Partnerships
17.4. Adoption of Innovative Technologies
17.4.1. Single Use Bioreactors
17.4.2. Novel Bioprocessing Techniques
17.4.3. Bioprocess Automation
17.5. Growing Popularity of the Quality by Design Principle in Bioprocessing
17.6. Increasing Focus on Niche Therapeutic Areas
17.7. Biosimilars Market to Contribute to Contract Service Revenues
17.8. Capability and Facility Expansions to Establish One Stop Shop Expertise
17.9. Increase in Financial In-flow and Outsourcing Budgets
17.10. Challenges Faced by Sponsors and Service Providers
17.10.1. Concerns Associated with Single Use Systems
17.10.2. Issues Related to Capacity Fluctuations
17.11. Concluding Remarks
18. INTERVIEW TRANSCRIPTS
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
